Comparative Pharmacology
Head-to-head clinical analysis: KETOCONAZOLE versus POSFREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOCONAZOLE versus POSFREA.
KETOCONAZOLE vs POSFREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, impairing ergosterol synthesis and disrupting fungal cell membrane integrity.
POSFREA is a carbapenem-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
200-400 mg orally once daily for superficial fungal infections; 400 mg orally once daily for systemic mycoses. Duration varies by indication.
IV 4 mg/kg once daily; infused over 90 minutes.
None Documented
None Documented
Biphasic elimination: initial half-life 2-4 hours, terminal half-life 6-10 hours in adults. In severe hepatic impairment, half-life may be prolonged up to 12-20 hours.
Clinical Note
moderateKetoconazole + Tranilast
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tranilast."
Clinical Note
moderateKetoconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tolfenamic acid."
Clinical Note
moderateKetoconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Nimesulide."
Clinical Note
moderate12 hours (range 10-14) in healthy adults; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Primarily metabolized in the liver; about 70% of the dose is excreted in feces via bile as metabolites, approximately 20-30% in urine (mostly as inactive metabolites), and less than 5% unchanged.
Renal (95%) as unchanged drug; biliary/fecal (5%).
Category C
Category C
Azole Antifungal
Azole Antifungal
Ketoconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Risedronic acid."